MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS… read more.
Anxiety, addiction, and other psychiatric disorders are often characterized by intense states of what scientists call arousal: The heart races, blood pressure readings rise, breaths shorten, and “bad”… read more.
Horizon Therapeutics plc has announced that the first patient has been enrolled in a Phase IV clinical trial evaluating the efficacy and safety of Tepezza for the treatment… read more.
In a recent study led by researchers at Massachusetts General Hospital (MGH) and Kings College Hospital published in Gut, people whose diets were based on healthy plant-based foods… read more.
By developing the first statistical model to finely characterize how ketamine anesthesia affects the brain, a team of researchers at MIT’s Picower Institute for Learning and Memory and… read more.
In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Targeting these T cells, which are… read more.
Chronic back pain affects upwards of 15 million adults in the US, racking up billions in healthcare costs and lost work days. Degeneration of the discs that cushion… read more.
The Bristol-Myers Squibb-Pfizer Alliance issued the following statement: We welcome the decision by the Court of Appeals for the Federal Circuit’s to affirm the U.S. District Court’s August… read more.
Researchers discover biomarkers that indicate early brain injury in extreme premature infants University of Vienna Extremely premature infants are at a high risk for brain damage. Researchers have… read more.
Based on a completed FDA review of a large randomized safety clinical trial, the FDA has concluded there is an increased risk of serious heart-related events such as… read more.
Researchers recommend increased prenatal surveillance for patients with sepsis and other serious infections University of California – San Francisco Individuals who are hospitalized during pregnancy due to sepsis… read more.
Impel NeuroPharma, Inc. announced that the FDA approved Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
